In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
|Videos|December 15, 2016
Product Demonstration: Equashield Pro
Watch a product demonstration of Equashield® Pro.
Advertisement
LAS VEGAS — Officials with Equashield unveiled the world's first robot with closed system transfer device (CSTD), dubbed the Equashield® Pro, at the ASHP Midyear Meeting held here earlier this month.
Watch it in action!
Advertisement
Related to this article
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Isatuximab on-body injector enables quick, hyaluronidase-free subcutaneous dosing, reducing reactions and easing multiple myeloma clinic workflows.
A summer PCAC vote pushes 6 peptide families toward the 503A bulks list—but the FDA's decision is still pending.
Parminder K. Judge, PhD, explains why eGFR and electrolytes should be monitored when diuretics are added to reach intensive BP targets in patients with CKD
The project maps how flu and HIV proteins enter cells, with the aim of developing longer-lasting vaccines.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
2
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
Pharmacists Positioned as Key Educators as Monoclonal Antibodies Emerge as COVID-19 Immunization Option
5